News for RCEL Stock

AVITA Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference AVITA Medical to Present at the Piper Sandler 37ᵗʰ Annual Healthcare Conference AVITA Medical to Host Investor Webinar Briefing AVITA® Medical Reports Third Quarter 2025 Financial Results Data Presented at the 2025 Southern Region Burn Conference Reinforce RECELL® System as a Standard of Care in Acute Wound Treatment AVITA Medical to Announce Third Quarter 2025 Financial Results AVITA Medical Welcomes Support for RECELL® in Burns in Australia AVITA Medical Announces CEO Transition CMS New Technology Add-On Payment Expands Access to RECELL® for Patients with Non-Burn Acute Wounds AVITA Medical Receives CE Mark for RECELL® GO, Enabling Commercialization Across Europe Real-World Data Shows Significant Reduction in Hospital Stay Using AVITA Medical’s RECELL® System AVITA Medical Announces September Investor Conference Participation AVITA Medical Successfully Completes Australian Equity Raise AVITA Medical to Host Investor Webinar Briefing AVITA Medical Reports Second Quarter 2025 Financial Results, Updates Full-Year Guidance, and Highlights Continued Clinical Innovation AVITA Medical Announces Appointment of Michael Tarnoff, MD, FACS, to its Board of Directors and Transition of Board Chair Role to Cary Vance AVITA Medical to Announce Second Quarter 2025 Financial Results AVITA Medical Highlights Largest Real-World Analysis Demonstrating Reduced Hospital Stay with RECELL AVITA Medical Announces First Clinical Publication Demonstrating Accelerated Autograft Readiness with Cohealyx™ AVITA Medical’s RECELL Platform Recognized for Surgical Innovation in 2025 MedTech Breakthrough Awards AVITA Medical’s Acute Wound Care Showcase 2025 Streams Live Today AVITA Medical Reports First Quarter 2025 Financial Results AVITA Medical to Host Acute Wound Care Showcase on May 13, 2025 AVITA Medical to Announce First Quarter 2025 Financial Results AVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025 AVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market Opportunity AVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical Scientific AVITA Medical to Present at TD Cowen’s 45ᵗʰ Annual Health Care Conference AVITA Medical to Host Investor Webinar Briefing AVITA Medical Reports Fourth Quarter and Full Year 2024 Financial Results AVITA Medical Updates Expected Fourth Quarter and Full Year 2024 Revenue, Provides 2025 Financial Guidance AVITA Medical Announces FDA Approval of RECELL GO mini, Optimizing Treatment for Smaller Wounds AVITA Medical Announces FDA 510(k) Clearance for Cohealyx, Expanding its Addressable Market AVITA Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference AVITA Medical to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference AVITA Medical Announces Exclusive Distribution Agreement to Expand to Australia and New Zealand AVITA Medical to Host Investor Webinar Briefing AVITA Medical Reports Third Quarter Financial Results AVITA Medical to Announce Third Quarter 2024 Financial Results AVITA Medical to Present at 2024 Cantor Global Healthcare Conference AVITA Medical to Participate in Lake Street’s 8th Annual Best Ideas Growth (BIG8) Conference AVITA Medical to Host Investor Webinar Briefing AVITA Medical Reports Second Quarter Financial Results AVITA Medical Names Robin VanDenburgh as SVP of U.S. Commercial Sales AVITA Medical Expands Portfolio with Unique Dermal Matrix to Advance Wound Care AVITA Medical to Announce Second Quarter 2024 Financial Results AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary AVITA Medical Achieves Milestone with First Case Using RECELL GO AVITA Medical Announces FDA Approval of RECELL GO AVITA Medical to Host Investor Webinar Briefing AVITA Medical Reports First Quarter Financial Results AVITA Medical to Announce First Quarter 2024 Financial Results AVITA Medical Updates Expected First Quarter 2024 Revenue AVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA Supplement AVITA Medical to Present at TD Cowen 44th Annual Health Care Conference AVITA Medical to Host Investor Webinar Briefing AVITA Medical Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance AVITA Medical to Announce Fourth Quarter and Full Year 2023 Financial Results AVITA Medical Announces Exclusive Distribution Agreement with Stedical Scientific AVITA Medical Announces Preliminary 2023 Financial Highlights, Provides 2024 Financial Guidance and Business Update AVITA Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference AVITA Medical to Host Investor Webinar Briefing AVITA Medical to Present at the Piper Sandler 35th Annual Healthcare Conference AVITA Medical Updates Full Year 2023 Guidance AVITA Medical Reports Third Quarter Financial Results with 51% Revenue Growth over the Same Period the Prior Year AVITA Medical Announces Distribution Partnership with PolyMedics Innovations to Expand to Europe AVITA Medical to Announce Third Quarter 2023 Financial Results AVITA Medical Announces Preliminary Third Quarter 2023 Financial Highlights and Secures up to $90 million of Non-Dilutive Debt Financing with OrbiMed to Support Growth Initiatives AVITA Medical Receives Best Product Award at the American Association for the Surgery of Trauma AVITA Medical to Present at the Cantor Global Healthcare Conference AVITA Medical to Participate in Upcoming Investor Conferences AVITA Medical to Host Investor Webinar Briefing AVITA Medical Reports Second Quarter Financial Results AVITA Medical to Announce Second Quarter 2023 Financial Results AVITA Medical Submits FDA PMA Supplement for RECELL GO AVITA Medical Rejoins the Russell 3000 Index AVITA Medical Announces FDA Approval of RECELL for Skin Repigmentation in Vitiligo Patients AVITA Medical Announces Appointment of David O’Toole as Chief Financial Officer AVITA Medical Announces FDA Approval of RECELL for Treatment of Full-Thickness Skin Defects AVITA Medical to Host Investor Webinar Briefing AVITA Medical Reports First Quarter Financial Results and Affirms Full Year Guidance AVITA Medical to Announce First Quarter 2023 Financial Results AVITA Medical Announces Update to Automation Device AVITA Medical Appoints New Non-Executive Member to the Board of Directors AVITA Medical Appoints New Non-Executive Member to the Board of Directors AVITA Medical to Present at the TD Cowen 43rd Annual Health Care Conference AVITA Medical to Host Investor Webinar Briefing AVITA Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance AVITA Medical to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide 2023 Financial Guidance AVITA Medical Announces Management Changes and Fourth Quarter 2022 Earnings Conference Call AVITA Medical Submits FDA PMA Application to Expand Indication to Vitiligo AVITA Medical Announces Results of 2022 Annual Meeting of Stockholders AVITA Medical Submits FDA PMA Supplement to Further Expand Indication to Soft Tissue Repair AVITA Medical® to Host Investor Webinar Briefing AVITA Medical Reports Third Quarter 2022 Financial Results AVITA Medical Announces Achievement of Co-Primary Endpoints in Updated Analysis of Pivotal Trial of RECELL® System for Soft Tissue Repair AVITA Medical Announces FDA Breakthrough Device Designations for the RECELL® System AVITA Medical to Announce Third Quarter 2022 Financial Results AVITA Medical Appoints Industry Leader James Corbett as Chief Executive Officer Investor Webinar Briefing AVITA Medical Achieves Positive Topline Pivotal Trial Results for Treatment of Stable Vitiligo Using the RECELL® System RECELL System Insurance Coverage Begins in Japan for Treatment of Acute Burns RECELL® System Data to be Presented at the Controversies and Conversations in Laser & Cosmetic Surgery Annual Meeting AVITA Medical Reports Second Quarter 2022 Financial Results AVITA Medical Announces Topline Results from Pivotal Trial in Patients with Soft-Tissue Injuries using the RECELL® System AVITA Medical to Announce Second Quarter 2022 Financial Results AVITA Medical Reports First Quarter 2022 Financial Results RECELL® System to be Highlighted at Upcoming Music City SCALE Multidisciplinary Dermatology Meeting AVITA Medical to Announce First Quarter 2022 Financial Results Avita Medical, Inc. Announces Resignation of Louis Drapeau from Board of Directors RECELL® System Data to be Presented at the American Burn Association Annual Meeting RECELL® System Vitiligo Clinical Trial Protocol to be Presented at the Global Vitiligo Foundation Annual Scientific Symposium AVITA Medical Announces Modification of BARDA Contract to Advance Development of RECELL® System in Soft Tissue Reconstruction Avita Medical, Inc. Signs Agreement with Premier, Inc. to Supply the RECELL® System to Hospitals and Health Systems Across the U.S. AVITA Medical Reports Quarter Ending December 31, 2021, and Transition Period July 1, 2021, to December 31, 2021, Financial Results The RECELL® System Receives PMDA Approval in Japan and AVITA Medical will Commercialize in Partnership with COSMOTEC, an M3 Group Company AVITA Medical to Present at the Cowen 42nd Annual Health Care Conference AVITA Medical Announces FDA Approval of New RECELL® System with Improved Ease of Use AVITA Medical to Announce Transition Period July 1, 2021 to December 31, 2021 Financial Results AVITA Medical to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference RECELL® System Data to be Presented at 44th Annual John A. Boswick Burn & Wound Care Symposium AVITA Medical Announces Preliminary Unaudited Results for the Quarter ended December 31, 2021 AVITA Medical Completes Enrollment in Pivotal Trial Evaluating the RECELL® System for Soft-Tissue Reconstruction AVITA Medical Establishes Proof of Concept for Novel Treatments Using Genetically-Modified Skin Cells AVITA Medical Completes Enrollment in Pivotal Trial Evaluating the RECELL® System for Repigmentation of Stable Vitiligo AVITA Medical, Inc. Announces Adjournment of 2021 Annual Stockholder Meeting AVITA Medical to Present at Upcoming Investor Conferences AVITA Medical Reports First Fiscal Quarter 2022 Financial Results AVITA Medical Announces Expanded Medicare Reimbursement to Outpatient Hospital and Ambulatory Surgical Centers Regional Burn Conferences Feature 12 RECELL® System Data Presentations by Prominent Burn Surgeons AVITA Medical to Announce Fiscal First Quarter 2022 Financial Results AVITA Medical to Present at the 2021 Cantor Virtual Global Healthcare Conference AVITA Medical to Participate at the Lake Street 2021 BIG5 Conference AVITA Medical Reports Fourth Quarter and Fiscal Year 2021 Financial Results FDA Approves IDE Amendment to a Single-Arm Design for AVITA Medical’s Pivotal Study of the RECELL® System for Vitiligo Treatment AVITA Medical to Announce Fiscal Fourth Quarter 2021 Financial Results AVITA Medical Announces Inclusion in the Russell 3000 Index AVITA Medical Announces Preliminary Fourth Quarter 2021 Financial Results U.S. Food and Drug Administration Approves Expanded Use of the RECELL® System for the Treatment of Extensive Burns and Pediatric Patients AVITA Medical, Inc. Appoints Two New Non-Executive Members to the Board of Directors AVITA Medical Reports Third Quarter 2021 Financial Results AVITA Medical to Announce Fiscal Third Quarter 2021 Financial Results New RECELL® System Data to be Presented at 43rd Annual John A. Boswick Burn & Wound Care Symposium 15 RECELL® System Abstracts Accepted for Presentation at 53ʳᵈ Annual American Burn Association Meeting AVITA Medical, Inc. Names Michael Holder as Chief Financial Officer Avita Medical, Inc. Announces Closing of Offering of 3,214,250 Shares of Common Stock AVITA Medical, Inc. Announces Pricing of Its Public Offering of Common Stock AVITA Medical, Inc. Announces Proposed Public Offering of Common Stock AVITA Medical to Present at Upcoming Investor Conferences AVITA Medical Reports Full Second Quarter 2021 Financial Results AVITA Medical to Present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference AVITA Medical to Announce Fiscal Second Quarter 2021 Financial Results AVITA Medical Announces Preliminary Fiscal Second Quarter 2021 Results AVITA Medical to Present at the J.P. Morgan 39th Annual Healthcare Conference RECELL® System Data Presented at American Burn Association Fall Regional Burn Conferences AVITA Therapeutics Appoints Kathy McGee as Chief Operating Officer AVITA Therapeutics to Participate at the Piper Sandler 32nd Annual Virtual Healthcare Conference AVITA Therapeutics Reports First Quarter 2021 Financial Results AVITA Therapeutics, Inc.: Results of 2020 Annual Meeting of Shareholders AVITA Therapeutics and the Houston Methodist Research Institute Enter into Collaboration to Explore Novel Approaches for Skin Rejuvenation AVITA Therapeutics, Inc. Announces Executive Change Avita Therapeutics, Inc. Announces Correction of Time for the Adjourned 2020 Annual Stockholder Meeting AVITA Therapeutics Announces Date Change for First Quarter 2021 Earnings Release and Conference Call AVITA Therapeutics, Inc. Announces Adjournment of 2020 Annual Stockholder Meeting AVITA Therapeutics to Participate in Upcoming Investor Conferences AVITA Therapeutics to Announce First Quarter 2021 Financial Results